Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
BUSINESS
Kissei Pharmaceutical to Transfer Marketing Rights for CABASER to Pfizer Japan
Kissei Pharmaceutical Co., Ltd announced on December 12 that effective April 1, 2012, the company would transfer marketing rights for Cabaser (cabergoline) Tab. 0.25 mg and 1.0 mg, a treatment for Parkinson’s disease, to its manufacturer Pfizer Japan Inc. Cabaser…
To read the full story
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





